CN1872280A - Composition of Chinese traditional medicine for treating allergic rhinitis, and preparation method - Google Patents
Composition of Chinese traditional medicine for treating allergic rhinitis, and preparation method Download PDFInfo
- Publication number
- CN1872280A CN1872280A CNA2005100734010A CN200510073401A CN1872280A CN 1872280 A CN1872280 A CN 1872280A CN A2005100734010 A CNA2005100734010 A CN A2005100734010A CN 200510073401 A CN200510073401 A CN 200510073401A CN 1872280 A CN1872280 A CN 1872280A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- chinese medicine
- water
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 56
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 15
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 15
- 239000000203 mixture Substances 0.000 title claims description 31
- 238000002360 preparation method Methods 0.000 title claims description 28
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 229940079593 drug Drugs 0.000 claims description 26
- 238000012360 testing method Methods 0.000 claims description 24
- 239000008187 granular material Substances 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 241000237636 Pheretima Species 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 241000756943 Codonopsis Species 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 239000006286 aqueous extract Substances 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 238000004809 thin layer chromatography Methods 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 4
- 239000013558 reference substance Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 150000002338 glycosides Chemical class 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 2
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- DLUOMMXONAIKQD-UHFFFAOYSA-N OC=O.ClC(Cl)Cl.CCOC(C)=O Chemical compound OC=O.ClC(Cl)Cl.CCOC(C)=O DLUOMMXONAIKQD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940124623 antihistamine drug Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000009400 out breeding Methods 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000026097 Factitious disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 1
- 229960003792 acrivastine Drugs 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- XRIVRYRXJYCJTQ-UHFFFAOYSA-N benzene;ethyl acetate;formic acid Chemical compound OC=O.CCOC(C)=O.C1=CC=CC=C1 XRIVRYRXJYCJTQ-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A Chinese medicine for treating allergic rhinitis is prepared from 8 Chinese-medicinal materials including astragalus root, earthworm, pilose asiabell root, ophiopogon root, etc. Its preparing process is also disclosed.
Description
Technical field
The invention belongs to the field of Chinese medicines, be specifically related to a kind of Chinese medicine composition of treatment of allergic rhinitis,
The preparation method that also relates to this Chinese medicine composition.
Background technology
Rhinitis is meant that inflammation appears in nasal membrane, shows as hyperemia or edema, and the patient nasal obstruction occurs through regular meeting, stream clear water tears, rhinocnesmus, throat's discomfort, symptoms such as cough.Owing to body is called allergic rhinitis (Allergic Rhinitis) to the irritated rhinitis that causes of certain material, it is a kind of of rhinitis, and can cause that a series of allergic conditions occur.Allergic rhinitis has become global commonly encountered diseases frequently-occurring disease, belongs to the I allergic reaction type, and it often has repeatedly.Though the multiple disease of whole body along with the development of the state of an illness, often can be brought out in the present nasal cavity of its initial stage multilist part.And should disease be mainly in western developed country, sickness rate is 10～20%, the area that has even up to 30%.In recent years, primary disease also is the gesture of rising in China's morbidity.Many scholars recognize that primary disease has become an international disease.
At present doctor trained in Western medicine adopts antihistamine drug's (as chlorphenamine, Acrivastine etc.), mast cell stabilizers preparations such as (as sodium cromoglicate eye liquid and oral medicine, tranilasts etc.) to treat more.And that said preparation often has is drowsiness, and consumption such as increases gradually at side effect, and its curative effect is also very dissatisfied.And, still there be not at present a kind of not only the having no adverse reaction of allergic rhinitis, curative effect but also definite and persistent medicine of being used for the treatment of in the world.Increasing western scholar is invested attention on the Chinese medicine.
Summary of the invention
An object of the present invention is to provide a kind of Chinese medicine composition of treatment of allergic rhinitis.
Another object of the present invention provides the preparation method of Chinese medicine composition of the present invention.
A further object of the present invention provides the purposes that Chinese medicine composition of the present invention is used for the treatment of disease.
For achieving the above object, a technical scheme of the present invention provides a kind of Chinese medicine composition of treatment of allergic rhinitis, it is characterized in that, this Chinese medicine composition is the compound Chinese medicinal preparation of making by by the following raw material of Chinese medicine medical material of following proportioning:
Radix Astragali 8-11 weight portion Pheretima 4-7 weight portion Radix Codonopsis 7-10 weight portion
Fructus Schisandrae Chinensis 4-7 weight portion 4-6 Radix Ophiopogonis weight portion Rhizoma Atractylodis Macrocephalae 2-5 weight portion
Radix Saposhnikoviae 3-6 weight portion Fructus Lycii 5-8 weight portion;
And can choose wantonly interpolation can in medicinal adjuvant (can leave out).The optimization formula of the crude drug of preparation Chinese medicine composition of the present invention is:
Radix Astragali 8-10 weight portion Pheretima 5-7 weight portion Radix Codonopsis 8-10 weight portion
Fructus Schisandrae Chinensis 5-7 weight portion 4-5 Radix Ophiopogonis weight portion Rhizoma Atractylodis Macrocephalae 2-4 weight portion
Radix Saposhnikoviae 3-5 weight portion Fructus Lycii 5-7 weight portion;
More preferably prescription is:
Radix Astragali 9-10 weight portion Pheretima 5-6 weight portion Radix Codonopsis 9-10 weight portion
Fructus Schisandrae Chinensis 6-7 weight portion 4.5-5 Radix Ophiopogonis weight portion Rhizoma Atractylodis Macrocephalae 2.5-3 weight portion
Radix Saposhnikoviae 3-4 weight portion Fructus Lycii 5.5-6 weight portion.
Another technical scheme of the present invention provides the preparation method of Chinese medicine composition of the present invention, and this method may further comprise the steps:
(1) with the Radix Astragali, Pheretima, Radix Codonopsis, Fructus Schisandrae Chinensis, Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, Radix Saposhnikoviae, Fructus Lycii totally 8 flavor crude drug add water distillation together according to said ratio, the used water yield is at least 6 times of used 8 flavor crude drug gross weights, collect distillate just, preferred this step (1) was carried out 0.5 hour under temperature more than 80 degrees centigrade at least, and more preferably this step (1) was carried out under 100 degree celsius temperature 1 hour;
(2) the first distillate that above-mentioned steps (1) is obtained carries out redistillation, collects re-distilled liquid;
(3) water that adds at least 4 times of amounts in the residue of above-mentioned steps (1) is again proceeded to extract, and gained water extract is concentrated make aqueous extract, adds ethanol and reach 60-80wt% to containing the alcohol amount in above-mentioned aqueous extract, and concentrate and make pure extractum; And
(4) the pure extractum mixing of re-distilled liquid that above-mentioned steps (2) is made and step (3) randomly adds adjuvant, promptly gets the present composition through suitable preparation process preparation.
In above-mentioned steps (1), to the not too many restriction of the employed water yield, the general used water yield is 6～15 times of used 8 flavor raw material weights.If the used water yield is very little, then distillation extraction is insufficient, if but the water yield of usefulness is too many, and the waste of water will be caused and time of distillation extraction can be prolonged.This step (1) was preferably carried out under 100 degree celsius temperature 1 hour.
In above-mentioned steps (2), resulting re-distilled liquid is preferably the 1-10% of distillate volume just.
In above-mentioned steps (3), described water extract preferably 60-70 degree centigrade down extract at least 0.5 hour, preferably extract and obtained in 1.5 hours, the density of described aqueous extract generally is controlled at 1-2 times of water density, and the density of described pure extractum generally is 1-2 times of water density.Preferably, the density of described aqueous extract is 1.15 times of water density, and the density of described pure extractum is 1.35 times of water density.
In order to improve the efficient of extraction, in the present invention in the preparation method of drug composition before 8 flavor crude drug are added water distillation, can choose this 8 flavor crude drug respectively and broken.
Chinese medicine composition provided by the invention has tonification lung spleen, the effect that consolidating superficial resistance is only had a stuffy nose.Be used for asthenia of pulmonosplenic qi, the caused nasal obstruction of instability of surface, rhinocnesmus, sneeze is frequent, thin nasal discharge such as water etc.; Allergic rhinitis is seen above-mentioned patient.
Chinese medicine composition provided by the invention can be made into various dosage forms, for example, and dosage forms such as granule, mixture, tablet, powder, honeyed pill, capsule, injection, drop, patch.The method and the used auxiliary agent that prepare these dosage forms are known to those skilled in the art, for example, can be referring to " pharmacy of Chinese materia medica " (Shanghai science tech publishing house, in November, 1986 publication), " pharmaceutic adjuvant complete works " (Sichuan science tech publishing house, publication in January nineteen ninety-five), " Chinese pharmacopoeia version in 2000 one (Chemical Industry Press, publish in January, 2000) etc.
Route of administration for Chinese medicine composition of the present invention does not have too much restriction yet, for example can be by modes such as oral, filling stomach, injection, transdermal, duodenal administration, intranasal administrations.
The present invention also provides a kind of method of treatment of allergic rhinitis, it is characterized in that, uses the Chinese medicine composition of the present invention of effective dose for the patient who needs treatment.Described allergic rhinitis comprises, for example the allergic rhinitis that causes such as pollen, dust, dirt demodicid mite.Described patient comprises the people, also comprises animals such as cat, Canis familiaris L..Described effective dose can change to some extent with factors such as the disease of patient order of severity, body weight, body constitution, age, ill history.But doctor or pharmacists have the ability to determine suitable dose for different patients.For example, can in the scope of 80～240mg/kg body weight, select, preferably in the scope of 100-150mg/kg body weight, select.
The specific embodiment
Embodiment 1
Respectively to the Radix Astragali, Pheretima, Radix Codonopsis, Fructus Schisandrae Chinensis, Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, Radix Saposhnikoviae, Fructus Lycii totally 8 the flavor crude drug choose and break process after, get Radix Astragali 900g, Pheretima 600g, Radix Codonopsis 900g, Fructus Schisandrae Chinensis 600g, Radix Ophiopogonis 450g, Rhizoma Atractylodis Macrocephalae 300g, Radix Saposhnikoviae 300g, Fructus Lycii 600g and place dynamic jar, add 6 times of medical material weight (drinking water of 4.65kg * 6=27.9kg), start agitator, distill, collect distillate just, again first distillate is carried out redistillation, collect re-distilled liquid, get 14ml, cold preservation is standby.Water extract that obtains to above-mentioned steps and medicinal residues add 4 times of medical material weight (drinking water of 4.65kg * 4=18.6kg), in 70 degrees centigrade of dynamic extraction 0.5 hour, obtain the water extract, filter, the filtrate decompression of this water extract is concentrated into 1.15 times of density (60～70 ℃) with respect to water, make aqueous extract, add ethanol and reach 70wt%, left standstill 24 hours, filter to containing the alcohol amount, reclaim the ethanol in the filtrate, and the density 1.35 times (60～70 ℃) that is concentrated into respect to water makes pure extractum 1kg.
Embodiment 2
In above-mentioned 1kg alcohol extractum, add soluble starch 250g, mannitol 250g, micropowder silica gel 100g, wet granulation.Above-mentioned re-distilled liquid 14ml adds 20ml ethanol (concentration is 95wt%) dissolving, sprays in the above-mentioned granule, makes the 1000g granule.
Test example 1
(1) detection of Radix Astragali effective ingredient
The preparation of need testing solution: get the granule 1.5g of embodiment 2 preparations, added 30ml methanol ultrasonic 30 minutes, filter, filtrate is concentrated into dried, and residue adds the 20ml water dissolution, uses water saturation n-butanol extraction 5 times, each 20ml merges n-butyl alcohol liquid, uses 1%NaOH solution washing three times, each 30ml, the washing secondary that the reuse n-butyl alcohol is saturated, each 30ml, reclaim n-butyl alcohol to doing, residue adds dissolve with methanol, and shifts standardize solution in the 5ml volumetric flask, add methanol constant volume to scale, shake up, promptly.
It is an amount of that precision takes by weighing in phosphorus pentoxide desiccator dry 24 hours astragaloside reference substance, adds methanol and make the solution that every 1ml contains 1mg, in contrast product solution.
Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw above-mentioned two kinds of each 5ul of solution, put respectively on same silica gel g thin-layer plate, placing the lower floor's solution that spends the night down for 10 ℃ with chloroform-methanol-water (13: 7: 2) is developing solvent, launch, take out, dry, spray is with 10% ethanol solution of sulfuric acid, and it is clear to be heated to the speckle colour developing at 105 ℃.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, daylight shows down identical sepia speckle; The 365nm ultraviolet light shows identical orange-yellow fluorescence speckle down.
Measure according to high performance liquid chromatography (an appendix VI of Pharmacopoeia of People's Republic of China version in 2000 D).With octadecylsilane chemically bonded silica is filler; With acetonitrile-water (36: 64) is mobile phase; Detector is an evaporative light scattering detector, and theoretical cam curve is calculated by the astragaloside peak should be not less than 2500, and accurate respectively reference substance solution 10ul and the need testing solution 10ul of drawing injects chromatograph of liquid, measures.As a result, the granule that makes of every 1g embodiment 2 contains the Radix Astragali with astragaloside (C
41H
68O
14) meter, be 0.2mg.
(2) detection of Pheretima effective ingredient
The preparation of need testing solution: get the granule 3g that embodiment 2 makes, add petroleum ether (30～60 ℃) 100ml, Soxhlet was extracted 4 hours, add 95% ethanol 100ml after drying, Soxhlet was extracted 6 hours again, be concentrated into dried, mix sample with 2g silica gel (100～200 order), add (dry method, Φ 1.5 * 40cm, column chromatography silica gel 100～200 orders) on the post that 8g silica gel is housed after volatilizing solvent, with chloroform-ethyl acetate-formic acid (5: 4: 1) eluting, collect 25ml, reclaim solvent, add the 1ml anhydrous alcohol solution as need testing solution to doing.
Other gets Pheretima control medicinal material 3g, makes control medicinal material solution according to preparing the same method of test sample.
Test according to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B), draw above-mentioned two kinds of each 4ul of solution, put respectively on same silica gel g thin-layer plate, with benzene-ethyl acetate-formic acid (2: 1: 0.3) is developing solvent, launch, take out, fully dry, spray is heated to speckle colour developing clear (about 0.5 hour) with 0.1% bromophenol blue alcoholic solution (alkalescence) at 120 ℃.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show identical yellow spotting.
(3) detection of effective components of fruit of Chinese wolfberry
The preparation of need testing solution: get the granule 1g that embodiment 2 makes, add the 100ml ethyl acetate, carry out Soxhlet and extracted 4 hours, be recycled to driedly, residue adds the 1ml dissolve with methanol as need testing solution.
Other gets Fructus Lycii control medicinal material 1g, makes control medicinal material solution according to preparing the same method of test sample.
According to thin layer chromatography (an appendix VI of Chinese Pharmacopoeia version in 2000 B) test, draw above-mentioned two kinds of solution 10ul respectively, put respectively on same silica gel g thin-layer plate, (9: 1: 1d) be developing solvent, expansion was taken out with ethyl acetate-chloroform-formic acid, dry, put under the 365nm ultraviolet light and inspect.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show blue fluorescence speckle.
Test example 2
Continuously through the oral cavity gastric infusion by granule 1,9, the 27g/ (kgd) of embodiment 2 preparations 7 days, pure lines or outbreeding system mice podedema due to the 13 μ g/kg of histamine all there are in various degree inhibitory action, the suppression ratio of C57b1/6J mice foot swelling is respectively 3.7%, 36.8%, 44.2%; To the swollen suppression ratio of Kunming kind outbreeding system mice foot is 28.9%, 38.5%, 58.5%; The suppression ratio that Cavia porcellus nasal cavity capillary permeability due to the histamine is raise is respectively 45.0%, 43.1%, 71.9%; Death time to the deadly Cavia porcellus of histamine prolongs 0.2,0.5,1.3 minute respectively; Rate elongation is respectively 7%, 16.7%, 43.3%, and heavy dose of group prolongs significantly (P＜0.05); Prompting is raise to allergic inflammation due to the histamine and vascular permeability by the granule of embodiment 2 preparation antagonism, and certain dose-effect relationship is arranged, continuously through the granule 0.8 of oral cavity gastric infusion by embodiment 2 preparations, 1.6,3.2g/ (kgd) 10 days to 1% egg protein sensitization, the suppression ratio of Cavia porcellus respiratory hypersensitivity cough number of times is 36.9% due to the 0.3% atomizing egg protein liquid, 51.3%, 56.3% all has significant inhibitory effect, and continuously the granule of above-mentioned various dosage is respectively the suppression ratio of the nose allergy of Cavia porcellus due to the 10%TDI: 6.5%, 10%, it is remarkable that 17.6% big-and-middle dosage suppresses the nose allergy.Prompting has certain antiallergic action and inflammatory mediator effect by the granule of embodiment 2 preparations, should be a kind of compound Chinese medicinal preparation of similar antihistamine drug.
3 acute toxicity tests of test example
The once oral granule dosage that is prepared by embodiment 2 of mice is equivalent to primary crude drug 403.3g crude drug/kg, can cause reactions such as independent activity of animals reduces, appetite descends, body weight gain is slow, and above-mentioned being reflected at recovered in two weeks substantially, do not cause animal dead.Illustrate that the oral above-mentioned particulate maximum tolerated dose of mice is greater than 403.3g crude drug/kg (being equivalent to 236 times of the clinical application dosage 1.8g of suggestion crude drug/kg, kg body weight meter).
The granule dosage of rat oral embodiment 2 preparations on the one is equivalent to primary crude drug 201.6g crude drug/kg, can cause degradation reaction under independent activity of animals minimizing, the appetite, and above-mentioned reaction all recovers in two weeks, does not cause animal dead.Illustrate that the particulate maximum tolerated dose in the oral Five Dragons of rat is greater than 201.6g crude drug/kg (being equivalent to 118 times of the clinical application dosage 1.8g of suggestion crude drug/kg, kg body weight meter).
Test example 4 long term toxicity tests
80 SD rats are divided into 4 groups, and male and female half and half gavage granule dosage by embodiment 2 preparation respectively and are equivalent to three dosage of primary crude drug 202,101,40g crude drug/(kgd) and normal saline negative control group (equal-volume normal saline), continuous 30 days.After the last administration 24 hours, 12 of every group of killing live rats, the femoral artery blood sampling is checked routine blood test, biochemical indicator, is done system's postmortem, gets 13 internal organs calculating organ coefficient of weighing, 24 internal organs malingerings inspections.The drug withdrawal of residue animal is done convalescent period and was observed 15 days, puts to death the as above whole indexs of work then and detects.Result of the test shows:
Each dosage rat appetite after gavaging by the granule of embodiment 2 preparations descends obviously, and feed consumption obviously reduces, and body weight obviously reduces, and the behavioral activity of animal is normal substantially.
Routine blood test and biochemical indicator result show, this medicine high dose can cause rat erythrocytosis, blood coagulation degree to increase (RBC ↑, PLT ↑).
Organ coefficient is the result show no obvious abnormalities.
In convalescent period, the unusual clinical indices of rat is all recovered normally not see retardance toxicity.
This result of the test shows, the long-term oral above-mentioned granule 202g crude drug of rat/(kgd) coagulation function is had certain influence, the safe dose of no toxicity be 〉=and the 101g crude drug/(kgd).
Rats gavaged continuous 30 days, can cause animal weight loss to occur in the administration phase, reactions such as feed consumption reduction by three dosage of the granule 202,101 of embodiment 2 preparation, 40g crude drug/(kgd).Hematological indices shows that high dose can cause that the animal coagulation function strengthens (PLT ↑).Blood biochemical is learned not obviously influence of index.In convalescent period, the every unusual index of rat is recovered normally substantially, does not see that retardance toxicity produces.
In sum, the long-term oral granule 202g crude drug/kg/d by embodiment 2 preparations of rat (be equivalent to clinical dosage 96 times) has certain influence to coagulation function, but this side effect is reversible, and drug withdrawal can recover after 15 days.The safe dose of no toxicity is 〉=101g crude drug/kg/d (be equivalent to the clinical application dosage of suggestion 48 times).
Although describe the present invention in conjunction with the preferred embodiments, but the present invention is not limited to the foregoing description, should be appreciated that, under the guiding of the present invention's design, those skilled in the art can carry out various modifications and improvement, and claims have been summarized scope of the present invention.
Claims (10)
1. the Chinese medicine composition of a treatment of allergic rhinitis is characterized in that, this Chinese medicine composition is the compound Chinese medicinal preparation of making by by the following raw material of Chinese medicine medical material of following proportioning:
Radix Astragali 8-11 weight portion Pheretima 4-7 weight portion Radix Codonopsis 7-10 weight portion
Fructus Schisandrae Chinensis 4-7 weight portion 4-6 Radix Ophiopogonis weight portion Rhizoma Atractylodis Macrocephalae 2-5 weight portion
Radix Saposhnikoviae 3-6 weight portion Fructus Lycii 5-8 weight portion.
2. Chinese medicine composition according to claim 1, wherein said crude drug proportioning is:
Radix Astragali 8-10 weight portion Pheretima 5-7 weight portion Radix Codonopsis 8-10 weight portion
Fructus Schisandrae Chinensis 5-7 weight portion 4-5 Radix Ophiopogonis weight portion Rhizoma Atractylodis Macrocephalae 2.-4 weight portion
Radix Saposhnikoviae 3-5 weight portion Fructus Lycii 5-7 weight portion.
3. Chinese medicine composition according to claim 2, wherein said crude drug proportioning is:
Radix Astragali 9-10 weight portion Pheretima 5-6 weight portion Radix Codonopsis 9-10 weight portion
Fructus Schisandrae Chinensis 6-7 weight portion 4.5-5 Radix Ophiopogonis weight portion Rhizoma Atractylodis Macrocephalae 2.5-3 weight portion
Radix Saposhnikoviae 3-4 weight portion Fructus Lycii 5.5-6 weight portion.
4. according to each described Chinese medicine composition of claim 1-3, wherein
According to " test determination of an appendix VIB-of Chinese pharmacopoeia version in 2000 thin layer chromatography, said composition shows the same color speckle on the stratographic relevant position of Radix Scutellariae first glycoside reference substance; And under the 365nm ultraviolet light, show same color fluorescence speckle;
According to " test determination of an appendix VIB-of Chinese pharmacopoeia version in 2000 thin layer chromatography, said composition shows identical color speckle on the stratographic relevant position of Pheretima control medicinal material;
According to " test determination of an appendix VIB-of Chinese pharmacopoeia version in 2000 thin layer chromatography, said composition show the fluorescence speckle of same color under the 365nm ultraviolet light on the stratographic relevant position of Fructus Lycii control medicinal material.
5. according to each described Chinese medicine composition of claim 1-3, it is granule, mixture, tablet, powder, honeyed pill, capsule, injection, drop or patch.
6. method for preparing any described Chinese medicine composition of claim 1-3, this method may further comprise the steps:
(1) with the Radix Astragali, Pheretima, Radix Codonopsis, Fructus Schisandrae Chinensis, Radix Ophiopogonis, the Rhizoma Atractylodis Macrocephalae, Radix Saposhnikoviae, Fructus Lycii totally 8 flavor crude drug add water distillation together according to said ratio, the used water yield is at least 6 times of used 8 flavor crude drug gross weights, collects distillate just;
(2) the first distillate that above-mentioned steps (1) is obtained carries out redistillation, collects re-distilled liquid;
(3) water that adds at least 4 times of amounts in the residue of above-mentioned steps (1) is again proceeded to extract, and gained water extract is concentrated make aqueous extract, adds ethanol and reach 60-80wt% to containing the alcohol amount in above-mentioned aqueous extract, and concentrate and make pure extractum; And
(4) the pure extractum mixing of re-distilled liquid that above-mentioned steps (2) is made and step (3) randomly adds adjuvant and carries out formulation preparation.
7. the described method of claim 6, wherein step (1) was carried out 0.5 hour under temperature more than 80 degrees centigrade at least.
8. the described method of claim 6, wherein the resulting re-distilled liquid of step (2) is the 1-10% of first distillate volume.
9. the described method of claim 6, wherein in step (3), described water extract extracts down at 60-70 degree centigrade and obtained at least 0.5 hour, the density of described aqueous extract be water density 1-2 doubly, the density of described pure extractum be water density 1-2 doubly.
10. the described method of claim 9, the density of wherein said aqueous extract is 1.15 times of water density, the density of described pure extractum is 1.35 times of water density.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100734010A CN100478015C (en) | 2005-05-30 | 2005-05-30 | Composition of Chinese traditional medicine for treating allergic rhinitis, and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100734010A CN100478015C (en) | 2005-05-30 | 2005-05-30 | Composition of Chinese traditional medicine for treating allergic rhinitis, and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1872280A true CN1872280A (en) | 2006-12-06 |
| CN100478015C CN100478015C (en) | 2009-04-15 |
Family
ID=37482988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100734010A Active CN100478015C (en) | 2005-05-30 | 2005-05-30 | Composition of Chinese traditional medicine for treating allergic rhinitis, and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100478015C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102366610A (en) * | 2011-08-30 | 2012-03-07 | 高永从 | Foot-bath traditional Chinese medicine composition for treating allergic rhinitis |
| CN105477469A (en) * | 2015-12-16 | 2016-04-13 | 张德骞 | Traditional Chinese medicine for treating lung-deficiency-related cold type anaphylactic rhinitis and preparation method of traditional Chinese medicine |
| CN105943940A (en) * | 2016-07-20 | 2016-09-21 | 孙丰卿 | Traditional Chinese medicine for treating allergic rhinitis and preparation method of preparation thereof |
| CN106074883A (en) * | 2016-08-05 | 2016-11-09 | 王豪鹏 | Ginseng stilbene antiallergic rhinitis particle and preparation method thereof |
-
2005
- 2005-05-30 CN CNB2005100734010A patent/CN100478015C/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102366610A (en) * | 2011-08-30 | 2012-03-07 | 高永从 | Foot-bath traditional Chinese medicine composition for treating allergic rhinitis |
| CN102366610B (en) * | 2011-08-30 | 2013-04-24 | 高永从 | Foot-bath traditional Chinese medicine composition for treating allergic rhinitis |
| CN105477469A (en) * | 2015-12-16 | 2016-04-13 | 张德骞 | Traditional Chinese medicine for treating lung-deficiency-related cold type anaphylactic rhinitis and preparation method of traditional Chinese medicine |
| CN105943940A (en) * | 2016-07-20 | 2016-09-21 | 孙丰卿 | Traditional Chinese medicine for treating allergic rhinitis and preparation method of preparation thereof |
| CN106074883A (en) * | 2016-08-05 | 2016-11-09 | 王豪鹏 | Ginseng stilbene antiallergic rhinitis particle and preparation method thereof |
| CN106074883B (en) * | 2016-08-05 | 2020-01-14 | 新疆金世康药业有限公司 | Ginseng and astragalus anti-allergic rhinitis granules and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100478015C (en) | 2009-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1806846A (en) | Chinese medicinal composition, its preparation process and quality control method | |
| CN101496870B (en) | Chinese medicinal composition for resolving phlegm and suppressing cough as well as preparation method and quality control method thereof | |
| CN104224811A (en) | Salvia miltiorrhiza medicine and preparation method thereof | |
| CN1762465A (en) | Rhinitis gel, its preparation method and quality control technology | |
| CN1958005A (en) | Combination of Chinese traditional medicine, preparation method, and quality control method | |
| CN100478015C (en) | Composition of Chinese traditional medicine for treating allergic rhinitis, and preparation method | |
| CN100415255C (en) | Composition of Chinese traditional medicine, and preparation method | |
| CN101040942A (en) | Active ingredient compound of Jianerqingjie solution and the control method | |
| CN102631526B (en) | Chinese medicinal composition for treating diabetes mellitus | |
| CN102920964B (en) | Traditional Chinese medicine preparation for curing cough | |
| CN1817898A (en) | Use of anti-inflammatory medicine for scheelite total saponin and its saponin compound | |
| CN1850838A (en) | Scutellarin raw material drug preparing method | |
| CN1989984A (en) | Chuanxiong rhizome effective ingredient, preparing method, preparation and use thereof | |
| CN1887324A (en) | Chinese composition and its prepn process and quality control method | |
| CN100336544C (en) | Chinese medicinal composition with beautifying function and method for preparing the same | |
| CN1194736C (en) | Composition for treating hepatitis B | |
| CN107913277A (en) | The purposes of the anti-uric acid nephropathy of tanshinone | |
| CN101129457A (en) | Methods of acquiring total tanshinone and preparing total phenolic acid | |
| CN1282468C (en) | Chinese medicine soft capsule Naodesheng and its preparing method | |
| CN1306949C (en) | Compound Chinese medicine formulation for tendon relaxation and anti-dampness, and its preapring method | |
| CN101249129B (en) | Chinese medicine extract combination and medicine use thereof | |
| CN1977888B (en) | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza | |
| CN1294948C (en) | Medicine for boosting qi, strengthening spleen and nourishing liver and kidney and its preparation method | |
| CN1891283A (en) | Chinese medicine composition, and its preparing method and quality control method | |
| CN100434092C (en) | Prescription containing sweet clover component and its formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Chengdu Chinese Medicine University Huasun Pharmaceutical Co., Ltd. Assignor: Pharmaceutical Factory, Chengdu Huashen Group Corp., Ltd. Contract record no.: 2011510000213 Denomination of invention: Traditional Chinese medicinal composition for treating allergic rhinitis and method for preparing same Granted publication date: 20090415 License type: Exclusive License Open date: 20061206 Record date: 20110826 |
|
| CP03 | Change of name, title or address |
Address after: 610000 Sichuan city of Chengdu Province Southwest Economic Development Zone Jinhua Road two No. 3 Patentee after: Chengdu Taihe health technology group Limited by Share Ltd Huashen pharmaceutical factory Address before: 610225 Sichuan city of Chengdu Province Southwest Economic Development Zone Jinhua Road 2 No. 3 Patentee before: Pharmaceutical Factory, Chengdu Huashen Group Corp., Ltd. |
|
| CP03 | Change of name, title or address | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Pharmaceutical Factory, Chengdu Huashen Group Corp., Ltd. Document name: Notification of Passing Examination on Formalities |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180509 Address after: 611731 B301-B310 room 3, 1168 Shu Xin Road, Chengdu high tech Zone, Sichuan. Patentee after: Chengdu Chinese Medicine University Huasun Pharmaceutical Co., Ltd. Address before: 610000 No. 3, two Jinhua Road, southwest aviation Economic Development Zone, Chengdu, Sichuan Patentee before: Chengdu Taihe health technology group Limited by Share Ltd Huashen pharmaceutical factory |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 610000 room b301-b311, 3rd floor, No. 1168 Shuxin Avenue, hi tech Zone, Chengdu, Sichuan Patentee after: Chengdu dahuashen Pharmaceutical Co.,Ltd. Address before: 611731 B301-B310 room 3, 1168 Shu Xin Road, Chengdu high tech Zone, Sichuan. Patentee before: CHENGDU UNIVERSITY OF TCM HUASUN PHARMACEUTICAL Co.,Ltd. |